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STATE-OF-THE-ART PAPER STATE-OF-THE-ART PAPER1315Surgical Approaches to Mitral RegurgitationDonald D. Glower
Surgical approaches to correct mitral regurgitation have evolved over the 50 years from the
first successful replacement. Glower reviews this evolution and the current state of the art for
both open surgical and percutaneous approaches to the mitral valve. Surgical incisions have
varied from full sternotomy down to percutaneous access only, with less invasiveness usually
requiring a trade-off of effectiveness or ease of application. Less invasive options in treating
mitral regurgitation may encourage higher risk patients to seek anatomic therapy, whether
surgical or percutaneous. Rapidly evolving technology will continue to be a dominant driver of
surgical approaches to mitral regurgitation, with increasing overlap and interaction with
percutaneous approaches.CLINICAL RESEARCH CLINICAL TRIALS1323Ivabradine Effective in Patients With Inappropriate Sinus TachycardiaRiccardo Cappato, Serenella Castelvecchio, Cristian Ricci, Elisabetta Bianco, Laura Vitali-Serdoz,
Tomaso Gnecchi-Ruscone Mario Pittalis, Luigi De Ambroggi, Mirco Baruscotti, Maddalena Gaeta,
Francesco Furlanello, Dario Di Francesco, Pier Paolo Lupo
Cappato and colleagues investigated the role of ivabradine in the treatment of symptomatic
inappropriate sinus tachycardia using a double-blind, placebo-controlled, crossover design.
Each of the 21 subjects underwent symptom evaluation and heart rate assessment at the start
and finish of each phase. While taking ivabradine, one-half of subjects experienced complete
elimination of their symptoms. These effects were associated with a significant reduction of
heart rate at rest (from 88 to 76 beats/min) with similar reductions in heart rate with
standing, during exercise, and 24 h mean. These findings suggest that ivabradine may be a
valuable tool for patients with inappropriate sinus tachycardia.
Editorial Comment: Melvin M. Scheinman, Vasanth Vedantham, p. 1330(continued on page A-26)
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1333Risks Associated With Stopping DAT
Early After DES May Be Lower Than AssumedIgnacio Ferreira-Gonza´lez, Josep R. Marsal, Aida Ribera, Gaietà Permanyer-Miralda,
Bruno Garcı´a-Del Blanco, Gerard Martı´, Purificacio´n Cascant, Mo´nica Masotti-Centol, Xavier Carrillo,
Josepa Mauri, Nuria Batalla, Eduard Larrousse, Eva Martı´n, Antonio Serra, José Ramo´n Rumoroso,
Rafael Ruiz-Salmero´n, Jose M de-la-Torre, Angel Cequier, Jose A. Go´mez-Hospital, Fernando Alfonso,
Victoria Martı´n-Yuste, Manel Sabatè, David Garcı´a-Dorado
Ferreira-Gonza´lez and colleagues measured the risks associated with dual antiplatelet therapy
(DAPT) discontinuation, both temporarily and permanently, during the first year after drug-
eluting stent (DES) implantation. Over 10% of patients interrupted at least 1 antiplatelet
drug during the first year after DES implantation, most temporarily, with a median duration
of 7 days. Discontinuation was followed by acute coronary syndrome in 4%, but the 1 year
rate of cardiac events was not higher in those who stopped DAPT than those who did not.
The authors conclude that DAPT discontinuation within the first year occurs frequently and
does not appear to have a large impact on cardiac risk.INTERVENTIONAL CARDIOLOGY13403 Months of DAPT May Be Long Enough With Endeavor ZESByeong-Keuk Kim, Myeong-Ki Hong, Dong-Ho Shin, Chung-Mo Nam, Jung-Sun Kim, Young-Guk Ko,
Donghoon Choi, Tae-Soo Kang, Byoung-Eun Park, Woong-Chol Kang, Seung-Hwan Lee, Jung-Han Yoon,
Bum-Kee Hong, Hyuck-Moon Kwon, Yangsoo Jang, for the RESET Investigators
The RESET trial compared the safety and efficacy of 3 months of dual antiplatelet therapy
(DAPT) compared to 12 months after drug-eluting stent (DES) implantation. Over 2,000
subjects were randomly assigned to either 3-month DAPT and Endeavor zotarolimus-eluting
stent (E-ZES) or 12-month DAPT and another type of DES in a noninferior study design.
There was no difference in the rate of the primary composite endpoint (cardiovascular death,
myocardial infarction, stent thrombosis, target-vessel revascularization, or bleeding) at 1 year
and no difference in the rate of stent thrombosis. These results suggest that 3 months of
DAPT may be adequate after E-ZES implantation.
Editorial Comment: Bernhard Witzenbichler, p. 1349(continued on page A-28)
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1352Trial of Cryoplasty or Conventional Balloon Post-Dilation of Nitinol Stents
for Nitinol Stents for Revascularization of Peripheral Arterial SegmentsSubhash Banerjee, Tony S. Das, Mazen S. Abu-Fadel, Eric J. Dippel, Nicolas W. Shammas, Daniel L. Tran,
Ahmad Zankar, Cyril Varghese, Kevin C. Kelly, Rick A. Weideman, Bertis B. Little, Robert F. Reilly,
Tayo Addo, Emmanouil S. Brilakis
Endovascular treatment of superficial femoral artery disease with nitinol self-expanding stents
is associated with high rates of in-stent restenosis in patients with diabetes mellitus. Though
the mechanism of cryoplasty continues to be debated, when delivered to the arterial wall, it
induces smooth muscle cell apoptosis while limiting cell necrosis. The COBRA trial
randomized 74 diabetic patients to post-dilation using cryoplasty or conventional balloons. At
12 months, binary restenosis was significantly lower in the cryoplasty group (29.3% vs.
55.8%). This preliminary trial suggests that cryotherapy balloon post-dilation can significantly
reduce the risk of restenosis in diabetic patients with peripheral vascular disease.Editorial Comment: Anand Prasad, p. 1360CARDIOVASCULAR RISK
1364Adolescence Risk Factors Are Predictive of
Coronary Artery Calcification in Middle AgeOlli Hartiala, Costan G. Magnussen, Sami Kajander, Juhani Knuuti, Heikki Ukkonen, Antti Saraste,
Irina Rinta-Kiikka, Sakari Kainulainen, Mika Kähönen, Nina Hutri-Kähönen, Tomi Laitinen,
Terho Lehtimäki, Jorma S. A. Viikari, Jaakko Hartiala, Markus Juonala, Olli T. Raitakari
Hartiala and colleagues examined the role of risk factor levels during adolescence in predicting
coronary artery calcium (CAC) in middle aged adults. CAC was assessed in 589 subjects
aged 40 to 46 years from the Cardiovascular Risk in Young Finns Study who had their
cardiac risk factors measured in 1980 (12 to 18 years) and again in 2007. Adolescent LDL-C
and systolic BP levels predicted CAC in adulthood independently of changes in these risk
factors over time. Elevated levels of LDL-C and systolic BP during adolescence are
independent predictors of adulthood CAC suggesting the need for early intervention to
prevent CAC.Editorial Comment: Harvey S. Hecht, p. 1371CARDIOVASCULAR RISK1374Lean Mass and Coronary MortalityCarl J. Lavie, Alban DeSchutter, Dharmendrakumar A. Patel, Abel Romero-Corral, Surya M. Artham,
Richard V. Milani
Prognosis in coronary heart disease (CHD) may be inversely related to obesity, which has
been termed the “obesity paradox”. Although obesity if often defined by body mass index
(BMI), Lavie and colleagues examined the separate contributions of lean mass index (LMI)
and body fat (BF) in 570 CHD patients followed for 3 years. Mortality was highest in the
group with low BF and low LMI, while low BF and low LMI predicted higher mortality.
Thus, both lean mass and body fat may contribute independently as predictors of mortality.(continued on page A-30)
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cCARDIOVASCULAR RISK1381Effects of Bariatric Surgery on Cardiac Ectopic FatBénédicte Gaborit, Alexis Jacquier, Frank Kober, Ines Abdesselam, Thomas Cuisset, Sandrine Boullu-Ciocca,
Olivier Emungania, Marie-Christine Alessi, Karine Clément, Monique Bernard, Anne Dutour
Gaborit and colleagues investigated the effect of bariatric surgery (BS)-induced weight loss on
cardiac ectopic fat (Efat). Cardiac Efat surrounds the myocardium and coronary arteries
without any separation between the cardiomyocytes or adventitia; it releases paracrinally
bioactive molecules which pass through the coronary wall by diffusion. 23 obese patients
underwent 1H-magnetic resonance spectroscopy to determine myocardial triglyceride content
(MTGC), MRI to assess epicardial fat volume (EFV), cardiac function, and CT visceral
abdominal fat (VAT) measurements at baseline and 6 months after BS. BS significantly
reduced body mass index (BMI), subcutaneous fat, VAT and EFV. There was no significant
change in MTGC. The loss in EFV was limited (27 %  11%) compared to VAT
diminution (40 %  19%) and was not correlated with percentage of BMI or VAT loss.
These results suggest that EFV may be triggered by different processes than other stores of
fat.Editorial Comment: Albert de Roos, p. 1390CARDIOVASCULAR RISK
1393Patients With Normal Submaximal Stress Echocardiography
at Higher Risk Than Those Who Achieve Target Heart RateHarikrishna Makani, Sripal Bangalore, Dan Halpern, Hetal G. Makwana, Farooq A. Chaudhry
Stress echocardiography (SE) is an important risk stratification tool for patients with known
or suspected coronary artery disease. The prognostic value of a normal but submaximal SE
(85% of maximal age predicted heart rate [APHR]) is conflicting. Bangalore and colleagues
performed a meta-analysis of 14 studies with 11, 542 patients followed-up for mean duration
of 32 months. The risk of hard events in patients with normal electrocardiogram and
echocardiographic images was 70% higher in those who did not achieve  85% of maximal
PHR. Patients with normal but submaximal stress echocardiography have a higher risk of
ardiovascular events than those who attain maximal stress test.(continued on page A-31)
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EHEART FAILURE
1402Marked Variation in Hospital Patterns of Use of
Positive Inotropic Agents in Patients With Heart FailureChohreh Partovian, Scott R. Gleim, Purav S. Mody, Shu-Xia Li, Haiyan Wang, Kelly M. Strait,
Larry A. Allen, Tara C. Lagu, Sharon-Lise T. Normand, Harlan M. Krumholz
Clinical guidelines recommend targeted use of positive inotropic agents in patients with acute
systolic heart failure, but the data are limited and the recommendations are not specific.
Partovian and colleagues analyzed data from 376 hospitals to study the use of these agents.
The risk-standardized rates of inotrope use ranged across hospitals from 0.9% to 44.6%
(median: 6.3%). Not only was there was wide variation in the use of inotropes, but also in
which inotrope was predominantly used which seemed to reflect an “individual institutional
effect.” Hospital rates or patterns of use were not associated with differences in length of stay
or risk-standardized mortality rates. These results highlight the need for robust clinical
research to identify which patients, if any, benefit from inotrope use.HEART RHYTHM DISORDERS
1410Spectrum and Prevalence of Mutations Involving BrS Susceptibility
Genes in a Cohort of Patients Referred for BRS Genetic TestingLia Crotti, Cherisse A. Kellen, David J. Tester, Silvia Castelletti, John R. Giudicessi, Margherita Torchio,
Argelia Medeiros-Domingo, Savastano Simone, Melissa L. Will, Federica Dagradi, Peter J. Schwartz,
Michael J. Ackerman
Ackerman and colleagues sought to determine the spectrum and prevalence of mutations in
the 12 Brugada syndrome (BrS)-susceptibility genes discovered to date. Comprehensive
mutational analysis of BrS1-12 susceptibility genes was performed in 129 unrelated patients
with possible/probable BrS. 27 patients (21%) had a putative pathogenic mutation, including
21 with an SCN5A mutation. The overall mutation yield was 23% in type 1 ECG pattern
only patients versus 17% in clinically diagnosed BrS patients. The rate was significantly higher
among men  20 years of age with clinically diagnosed BrS, and among patients who had a
rolonged PQ interval.
ditorial Comment: Elizabeth S. Kaufmann, p. 1419(continued on page A-32)
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1421Risk of AF in Diabetics Related to Obesity and
Hypertension Rather than DiabetesTobias Schoen, Aruna D. Pradhan, Christine M. Albert, David Conen
Prior studies have found an increased risk of incident atrial fibrillation (AF) among
individuals with type 2 diabetes (T2D), but it remains unclear if this risk is related to diabetes
or its associated metabolic changes. Schoen and colleagues reviewed data from  30,000
female health professionals who participated in the Women’s Health Study. Women with
T2D were nearly twice as likely to develop new-onset AF as those without T2D. In
multivariable analyses adjusting for baseline confounders, this risk was substantially attenuated,
and became insignificant after adjustment for changes in AF risk factors over time. While this
study confirms a significant relationship between T2D and incident AF, the data suggest that
this increased risk is mainly mediated by changes of other AF risk factors, particularly obesity
and hypertension.
